Phi Pharma SA is developing a new class of anti-cancer drugs: peptide drug conjugates effective in multiple human cancers using an innovative mechanism of cell entry: novel sugar-based drug targets.
Phi Pharma SA is developing a new class of anti-cancer drugs: peptide drug conjugates effective in multiple human cancers using an innovative mechanism of cell entry: novel sugar-based drug targets.
Place du Midi 36, 1950 Sion, Switzerland